Sudeep Pharma IPO Details: Price, Dates & Financials

Pre-issue shareholding: 111,346,602 shares. Post-issue shareholding: 112,948,626 shares.

Sudeep Pharma IPO is a Fresh Capital-cum-Offer for Sale issue. Issue type: Bookbuilding IPO. Face value is ₹1.

The UPI mandate for Sudeep Pharma IPO needs to be accepted by 25 Nov 2025. Approve the mandate request in your UPI app before the deadline, otherwise your bid may be rejected.

The Red Herring Prospectus (RHP) of Sudeep Pharma IPO is available on the website of the lead manager and the stock exchange (NSE & BSE) — see the lead manager links on the main page.

The DRHP is the initial offer document filed for regulatory review, while the RHP includes updated disclosures, final issue details, and the price band (when announced). Comparing both documents helps investors identify changes in the Sudeep Pharma IPO's financial information, risks, and offer terms before investing in the Sudeep Pharma IPO. Reviewing both documents provides a clearer understanding of the Sudeep Pharma IPO before making an investment decision.

The DRHP and RHP of the Sudeep Pharma IPO disclose potential risks related to the company's business, financial performance, legal matters, and industry conditions. Reviewing these documents helps investors identify potential concerns about the Sudeep Pharma IPO, evaluate the Sudeep Pharma IPO's risk factors, and make a more informed decision before investing in the Sudeep Pharma IPO.